FMP
Evoke Pharma, Inc.
EVOK
NASDAQ
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
5.07 USD
-0.42 (-8.28%)
About
ceo
Mr. Matthew J. D'Onofrio MBA
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.evokepharma.comexchange
NASDAQ
Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
CIK
0001403708
ISIN
US30049G2030
CUSIP
30049G104
Address
420 Stevens Avenue
Phone
858 345 1494
Country
US
Employee
4
IPO Date
Sep 25, 2013
Key Executives
